Indivior PLC Form 4 insider transactions

Woodrow D Anderson, Chief Accounting Officer of Indivior Plc, purchased 1,500 shares of common stock on August 5, 2026 for $36.28 per share.

Indivior and Supernus Pharmaceuticals announce an all-stock merger of equals to create a leading U.S. biopharmaceutical company focused on central nervous system diseases.

Indivior Pharmaceuticals and Supernus Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical company with significant scale and projected annual cost synergies of at least $125 million.

Indivior Pharmaceuticals announced robust second quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year guidance, alongside progress on its merger with Supernus.

Indivior Pharmaceuticals and Supernus Pharmaceuticals announce a merger of equals, creating a diversified CNS biopharmaceutical company named Supernus, Inc.

Christian Heidbreder, Chief Scientific Officer of Indivior Plc, sold 18,586 shares of common stock on July 10, 2026 for $41.14 per share.

Chief Scientific Officer Christian Heidbreder sold 18,586 shares of Indivior common stock via a Rule 10b5-1 trading plan.

Indivior Pharmaceuticals Chief Financial Officer, Ryan Preblick, has sold 36,000 shares of common stock for $37.70 per share, executed under a pre-arranged 10b5-1 trading plan.

Director Juliet Thompson reported transactions involving Indivior Pharmaceuticals common stock, including the acquisition of Restricted Stock Units and the sale of shares to cover tax withholding.

Indivior Pharmaceuticals, Inc. reports that Director Keith Humphreys was granted 6,518 Restricted Stock Units (RSUs) on May 13, 2026.

Indivior Pharmaceuticals, Inc. reports a stock grant to Director Stuart A. Kingsley, involving 6,518 Restricted Stock Units.

Daniel A. Ninivaggi, a Director at Indivior Pharmaceuticals, Inc., was granted 6,518 Restricted Stock Units (RSUs) on May 13, 2026.

Indivior Pharmaceuticals, Inc. reports a grant of Restricted Stock Units to Director Barbara Ryan.

Indivior Pharmaceuticals, Inc. reports a stock grant to Director Mark Stejbach, comprising 6,518 Restricted Stock Units.

Indivior Pharmaceuticals CFO Ryan Preblick reported the vesting of 6,302 restricted stock units and the subsequent sale of 2,843 shares to cover tax obligations.

Indivior Pharmaceuticals director Barbara Ryan acquired 8 shares of common stock in a pre-planned transaction.

Indivior Pharmaceuticals' Chief Accounting Officer, Woodrow D. Anderson, reported the vesting of performance and restricted stock units, alongside associated tax withholding transactions.

Indivior Pharmaceuticals CFO Ryan Preblick reported the vesting of performance stock units and subsequent tax-related share withholding.

Indivior Pharmaceuticals' Chief Legal Officer, Jeffrey W. Burris, acquired 79,893 shares through PSU vesting and sold 36,032 shares for tax obligations.

Indivior Pharmaceuticals' Chief Scientific Officer, Christian Heidbreder, saw 101,544 performance stock units vest, followed by a sale of 45,797 shares to cover tax obligations.

Indivior Pharmaceuticals' Chief Accounting Officer, Woodrow D. Anderson, reported the grant of restricted stock units and the vesting of performance stock units.

Indivior Pharmaceuticals' Chief Financial Officer, Ryan Preblick, reported the acquisition of 37,358 restricted stock units and 113,510 performance stock units.

Indivior Pharmaceuticals' Chief Legal Officer, Jeffrey W. Burris, reported the grant of restricted stock units and performance stock units.

Indivior Pharmaceuticals' Chief Scientific Officer, Christian Heidbreder, received significant equity awards, including Restricted Stock Units and Performance Stock Units.

Indivior Pharmaceuticals' Chief Commercial Officer, Patrick A. Barry, was granted 31,380 restricted stock units, vesting over three years.

Indivior Pharmaceuticals, Inc. CEO Joseph Ciaffoni was granted 79,976 restricted stock units, vesting over three years.

Indivior Pharmaceuticals, Inc. director Stuart A. Kingsley received a grant of 3,722 Restricted Stock Units, increasing his beneficial ownership.

Indivior Pharmaceuticals Director David E. Wheadon was granted 5,955 Restricted Stock Units, increasing his beneficial ownership to 20,350 shares.

Indivior Pharmaceuticals, Inc. Director Barbara Ryan was granted 3,722 Restricted Stock Units, vesting before the next annual meeting.

Indivior Pharmaceuticals Director Daniel A. Ninivaggi was granted 3,722 Restricted Stock Units, increasing his direct beneficial ownership to 20,645 shares.